The endocannabinoid system in appetite regulation and treatment of obesity.
Journal
Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
23
08
2024
received:
13
12
2023
accepted:
03
09
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
18
9
2024
Statut:
ppublish
Résumé
The endocannabinoid system (ECS) is a complex cell-signaling system that is responsible for maintaining homeostasis by modulating various regulatory reactions in response to internal and environmental changes. The influence of ECS on appetite regulation has been a subject of much recent research, however, the full extent of its impact remains unknown. Current evidence links human obesity to ECS activation, increased endocannabinoid levels in both central and peripheral tissues, along with cannabinoid receptor type 1 (CBR1) up-regulation. These findings imply the potential pharmacological use of the ECS in the treatment of obesity. Here, we present various pathophysiological processes in obesity involving the ECS, highlighting different pharmacological options for modulating endocannabinoid activity to treat obesity. However, the potential of those pharmacological possibilities remains under investigation and requires further research.
Substances chimiques
Endocannabinoids
0
Receptor, Cannabinoid, CB1
0
Anti-Obesity Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70009Informations de copyright
© 2024 The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.
Références
Farrimond JA, Mercier MS, Whalley BJ, Williams CM. Cannabis sativa and the endogenous cannabinoid system: therapeutic potential for appetite regulation. Phytother Res. 2011;25(2):170‐188.
Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516‐525.
Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol. 1998;38(1):179‐200.
Toczek M, Malinowska B. Enhanced endocannabinoid tone as a potential target of pharmacotherapy. Life Sci. 2018;204:20‐45.
Kirkham TC. Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol. 2005:16(5‐6):297‐313.
Matheson J, Zhou XMM, Bourgault Z, Le Foll B. Potential of fatty acid amide hydrolase (FAAH), Monoacylglycerol lipase (MAGL), and Diacylglycerol lipase (DAGL) enzymes as targets for obesity treatment: a narrative review. Pharmaceuticals. 2021;14(12):1316.
Rodríguez‐Serrano LM, Chávez‐Hernández ME. Role of the CB2 cannabinoid receptor in the regulation of food intake: a systematic review. Int J Mol Sci 2023 Dec;24(24):17516.
Jordan CJ, Xi ZX. Progress in brain cannabinoid CB2 receptor research: from genes to behavior. Neurosci Biobehav Rev. 2019;98:208‐220.
Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2‐Arachidonyl Glycerol Is a Full Agonist through Human Type 2 Cannabinoid Receptor: Antagonism by Anandamide. Mol Pharmacol. 2000;57(5):1045‐1050.
Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):833.
Howlett A, Blume L, Dalton G. CB1 cannabinoid receptors and their associated proteins. CMC. 2010;17(14):1382‐1393.
Schulz P, Hryhorowicz S, Rychter AM, et al. What role does the endocannabinoid system play in the pathogenesis of obesity? Nutrients. 2021;13(2):373.
Wright NJD. A review of the direct targets of the cannabinoids cannabidiol, Δ9‐tetrahydrocannabinol, N‐arachidonoylethanolamine and 2‐arachidonoylglycerol. AIMS Neuroscience. 2024;11(2):144‐165.
Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci. 2005;8(5):585‐589.
Kolotkin RL, Meter K, Williams GR. Quality of life and obesity. Obes Rev. 2001;2(4):219‐229.
Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126(11):1477‐1500.
Obesity and overweight [Internet]. 2024 [cited 2024 Aug 19]. https://www.who.int/news‐room/fact‐sheets/detail/obesity‐and‐overweight
Viveros M, De Fonseca F, Bermudez‐Silva F, McPartland J. Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. EMIDDT. 2008;8(3):220‐230.
Harrold JA, Williams G. The cannabinoid system: a role in both the homeostatic and hedonic control of eating? Br J Nutr. 2003;90(4):729‐734.
Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. 1998;63(8):PL113–7:PL113‐PL117.
Bell‐Anderson KS, Aouad L, Williams H, et al. Coordinated improvement in glucose tolerance, liver steatosis and obesity‐associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice. Int J Obes. 2011;35(12):1539‐1548.
Fong TM, Guan XM, Marsh DJ, et al. Antiobesity efficacy of a novel Cannabinoid‐1 receptor inverse Agonist,N‐[(1S,2S)‐3‐(4‐Chlorophenyl)‐2‐(3‐cyanophenyl)‐1‐methylpropyl]‐2‐methyl‐2‐{[5‐(trifluoromethyl)pyridin‐2‐yl]oxy}propanamide (MK‐0364), in rodents. J Pharmacol Exp Ther. 2007;321(3):1013‐1022.
Gary‐Bobo M, Elachouri G, Gallas JF, et al. Rimonabant reduces obesity‐associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology. 2007;46(1):122‐129.
Tam J, Godlewski G, Earley BJ, et al. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet‐induced obesity. American Journal of Physiology‐Endocrinology and Metabolism. 2014;306(4):E457‐E468.
Szanda G, Jourdan T, Wisniewski É, et al. Cannabinoid receptor type 1 (CB(1)R) inhibits hypothalamic leptin signaling via β‐arrestin1 in complex with TC‐PTP and STAT3. iScience. 2023;26(7):107207.
Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes. 2005;29(7):755‐759.
Miralpeix C, Reguera AC, Fosch A, et al. Hypothalamic endocannabinoids in obesity: an old story with new challenges. Cell Mol Life Sci. 2021;78(23):7469‐7490.
Rossi F, Punzo F, Umano GR, Argenziano M, Giudice EMD. Role of cannabinoids in obesity. Int J Mol Sci. 2018;19(9):2690.
Cardinal P, André C, Quarta C, et al. CB1 cannabinoid receptor in SF1‐expressing neurons of the ventromedial hypothalamus determines metabolic responses to diet and leptin. Molecular Metabolism. 2014;3(7):705‐716.
Tam J, Cinar R, Liu J, et al. Peripheral Cannabinoid‐1 receptor inverse Agonism reduces obesity by reversing leptin resistance. Cell Metab. 2012;16(2):167‐179.
Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia. 2008;51(8):1356‐1367.
Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112(3):423‐431.
Morozov YM, Koch M, Rakic P, Horvath TL. Cannabinoid type 1 receptor‐containing axons innervate NPY/AgRP neurons in the mouse arcuate nucleus. Molecular Metabolism. 2017;6(4):374‐381.
Tarragon E, Moreno JJ. Cannabinoids, chemical senses, and regulation of feeding behavior. Chem Senses. 2019;44(2):73‐89.
Cota D. Role of the endocannabinoid system in energy balance regulation and obesity. In: Korbonits M, ed. Frontiers of Hormone Research. KARGER; 2008 [cited 2024 Aug 19]:135‐145.
Koch M, Varela L, Kim JG, et al. Hypothalamic POMC neurons promote cannabinoid‐induced feeding. Nature. 2015;519(7541):45‐50.
Thompson NM, Gill DAS, Davies R, et al. Ghrelin and des‐Octanoyl ghrelin promote Adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone Secretagogue receptor. Endocrinology. 2004;145(1):234‐242.
Mani BK, Castorena CM, Vianna CR, et al. Combined loss of ghrelin receptor and cannabinoid CB1 receptor in mice decreases survival but does not additively reduce body weight or eating. Neuroscience. 2020;447:53‐62.
Senin LL, Al‐Massadi O, Folgueira C, et al. The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake. PLoS One. 2013;8(11):e80339.
Watkins BA, Kim J. The endocannabinoid system: directing eating behavior and macronutrient metabolism. Front Psychol 2015 Jan 6;5:1506. doi:10.3389/fpsyg.2014.01506
Owyang C, Heldsinger A. Vagal control of satiety and hormonal regulation of appetite. J Neurogastroenterol Motil. 2011;17(4):338‐348.
Kowalski CW, Ragozzino FJ, Lindberg JEM, et al. Cannabidiol activation of vagal afferent neurons requires TRPA1. J Neurophysiol. 2020;124(5):1388‐1398.
DiPatrizio NV, Astarita G, Schwartz G, Li X, Piomelli D. Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci USA. 2011;108(31):12904‐12908.
Després JP, Golay A, Sjöström L. Rimonabant in Obesity‐Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005 Nov 17;353(20):2121‐2134. doi: 10.1056/NEJMoa044537.
Di Marzo V, Goparaju SK, Wang L, et al. Leptin‐regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410(6830):822‐825.
Wei Q, Lee JH, Wu CS, et al. Metabolic and inflammatory functions of cannabinoid receptor type 1 are differentially modulated by adiponectin. World J Diabetes. 2021;12(10):1750‐1764.
Engeli S. Peripheral metabolic effects of endocannabinoids and cannabinoid receptor blockade. Obes Facts. 2008;1(1):8‐15.
Bermudez‐Silva FJ, Sanchez‐Vera I, Suárez J, et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol. 2007;565(1–3):207‐211.
Verty ANA, Stefanidis A, McAinch AJ, Hryciw DH, Oldfield B. Anti‐obesity effect of the CB2 receptor agonist JWH‐015 in diet‐induced obese mice. Nadal A, PLoS One. 2015;10(11):e0140592.
Romero‐Zerbo SY, Garcia‐Gutierrez MS, Suárez J, et al. Overexpression of cannabinoid CB2 receptor in the brain induces Hyperglycaemia and a lean phenotype in adult mice. J Neuroendocrinol. 2012;24(8):1106‐1119.
Agudo J, Martin M, Roca C, et al. Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia. 2010;53(12):2629‐2640.
O'Keefe L, Vu T, Simcocks AC, et al. Treatment of diet‐induced obese rats with CB2 agonist AM1241 or CB2 antagonist AM630 reduces leptin and alters Thermogenic mRNA in adipose tissue. Int J Mol Sci. 2023;24(8):7601.
Schmitz K, Mangels N, Häussler A, Ferreirós N, Fleming I, Tegeder I. Pro‐inflammatory obesity in aged cannabinoid‐2 receptor‐deficient mice. Int J Obes. 2016;40(2):366‐379.
Iannotti FA, Vitale RM. The endocannabinoid system and PPARs: focus on their Signalling crosstalk, action and transcriptional regulation. Cells. 2021;10(3):586.
Hempel B, Crissman M, Pari S, et al. PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine‐ and cannabinoid‐mediated behavior in mice. Mol Psychiatry. 2023;28(10):4203‐4214.
Lago‐Fernandez A, Zarzo‐Arias S, Jagerovic N, Morales P. Relevance of peroxisome proliferator activated receptors in multitarget paradigm associated with the endocannabinoid system. Int J Mol Sci. 2021;22(3):1001.
O'Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173(12):1899‐1910.
Osei‐Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet‐induced obesity. J Clin Invest. 2005;115(5):1298‐1305.
Kim J, Li Y, Watkins BA. Fat to treat fat: emerging relationship between dietary PUFA, endocannabinoids, and obesity. Prostaglandins Other Lipid Mediat. 2013;104–105:32‐41.
Hansen HS, Artmann A. Endocannabinoids and nutrition. J Neuroendocrinol 2008 May;20(s1):94–9.
Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF. Biomarkers of endocannabinoid system activation in severe obesity. Biomarkers of Endocannabinoid System Activation in Severe Obesity. Vol 5. In; 2010:e8792.
Richey JM, Woolcott O. Re‐visiting the endocannabinoid system and its therapeutic potential in obesity and associated diseases. Curr Diab Rep. 2017;17(10):99.
Matias I, Gatta‐Cherifi B, Tabarin A, Clark S, Leste‐Lasserre T, Marsicano G. Endocannabinoids measurement in human saliva as potential biomarker of obesity. Endocannabinoids Measurement in Human Saliva as Potential Biomarker of Obesity. Vol 7. In; 2012.
Blüher M, Engeli S, Klöting N, Berndt J, Fasshauer M, Bátkai S. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55:3053‐3060.
Monteleone P, Piscitelli F, Scognamiglio P, et al. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2‐Arachidonoyl‐glycerol in healthy humans: a pilot study. J Clin Endocrinol Metab. 2012;97(6):E917‐E924.
Aguilera Vasquez N, Nielsen DE. The endocannabinoid system and eating Behaviours: a review of the current state of the evidence. Curr Nutr Rep. 2022;11(4):665‐674.
Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54(10):2838‐2843.
Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and Tolerability of Rimonabant in Overweight or Obese Patients with Type 2 Diabetes: a Randomised Controlled Study. Lancet. 2006;368(9548):1660‐1672.
Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Effects of the Cannabinoid‐1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1‐Year Experience from the RIO‐Europe Study. 2005;365(9468):1389‐1397.
Nguyen T, Thomas BF, Zhang Y. Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: current approaches for therapeutics development. CTMC. 2019;19(16):1418‐1435.
Pi‐Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. RIO‐North America study group FT. effect of Rimonabant, a Cannabinoid‐1 receptor blocker, on weight and Cardiometabolic risk factors in overweight or obese patients: RIO‐North America: a randomized controlled trial. JAMA. 2006;295(7):761‐775.
Bosquez‐Berger T, Szanda G, Straiker A. Requiem for Rimonabant: therapeutic potential for cannabinoid CB1 receptor antagonists after the fall. DDC. 2023;2(3):689‐707.
Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight‐loss drug rimonabant: a meta‐analysis of randomised trials. Lancet. 2007;370(9600):1706‐1713.
Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17(9):623‐639.
Dasram MH, Walker RB, Khamanga SM. Recent advances in endocannabinoid system targeting for improved specificity: strategic approaches to targeted drug delivery. IJMS. 2022;23(21):13223.
Deveaux V, Cadoudal T, Ichigotani Y, Teixeira‐Clerc F, Louvet A, Manin S, et al. Cannabinoid CB2 receptor potentiates obesity‐associated inflammation, insulin resistance and hepatic steatosis. PLoS One. 2009;4(6):e5844
Rossi F, Bellini G, Luongo L, et al. Cannabinoid receptor 2 as Antiobesity target: inflammation, fat storage, and Browning modulation. J Clin Endocrinol Metab. 2016;101(9):3469‐3478.
Gregus AM, Buczynski MW. Druggable Targets in Endocannabinoid Signaling. In: Kihara Y, Editor. Druggable Lipid Signaling Pathways [Internet]. Cham: Springer International Publishing; 2020:177‐201.
Knani I, Earley BJ, Udi S, et al. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader–Willi syndrome. Molecular Metabolism. 2016;5(12):1187‐1199.
Cannabis for Obesity Trial [Internet]. ClinicalTrials.gov. National Library of Medicine. 2024. Accessed September 12, 2024. https://clinicaltrials.gov/study/NCT06137365
Reis MG, Ferreira AJF, Sohouli MH, Taimeirão DR, Vieira RAL, Guimarães NS. Effect of cannabis and subproducts on anthropometric measures: a systematic review and meta‐analysis. Int J Obes. 2024;48(1):44‐54.
Muniyappa R, Sable S, Ouwerkerk R, et al. Metabolic effects of chronic cannabis smoking. Diabetes Care. 2013;36(8):2415‐2422.
Fearby N, Penman S, Thanos P. Effects of Δ9‐Tetrahydrocannibinol (THC) on obesity at different stages of life: a literature review. IJERPH. 2022;19(6):3174.
Harding SD, Sharman JL, Faccenda E, et al. The IUPHAR/BPS guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2018;46(D1):D1091‐D1106.
Alexander SPH, Christopoulos A, Davenport AP, et al. The concise guide to PHARMACOLOGY 2023/24: G protein‐coupled receptors. British J Pharmacology [Internet]. 2023;180(S2):S23‐S144. doi:10.1111/bph.16177